Delay subsequent pregnancy until beta-hCG undetectable
Minimum 3-month delay recommended after MTX for folate repletion
Discuss optimal contraception during monitoring period
Patient Discharge Instructions
copy discharge instructions
What to watch for and return immediately
Return to the emergency department immediately if
Sudden worsening abdominal or pelvic pain
Fainting or near-fainting
Shoulder or neck pain (may mean internal bleeding)
Heavy vaginal bleeding soaking more than one pad per hour
Feeling very dizzy, weak, or unable to stand
Rapid heartbeat or chest pain
After methotrexate injection
Avoid
Folic acid vitamins and prenatal vitamins until your doctor says it is safe
NSAIDs such as ibuprofen and naproxen — use acetaminophen instead for pain
Alcohol during and after treatment until resolution
Sexual intercourse until your doctor confirms resolution
Sun exposure as methotrexate increases sun sensitivity
Some pain and cramping in the first few days after injection is common
This is called the separation pain
Mild-to-moderate pain normal in days 3-7
Severe or worsening pain after day 1 needs emergency evaluation
Blood tests are required to confirm the medication is working
Return for beta-hCG blood test on day 4
Return for beta-hCG blood test on day 7
Your levels may rise initially before falling — this is expected
Follow-up plan
Blood test appointments booked before leaving the department
Day 4 and day 7 post-MTX beta-hCG
Weekly thereafter until undetectable
Gynecology or outpatient OB/GYN clinic within 1 week
Earlier if symptoms change
Do not try to conceive until
Beta-hCG is undetectable
At least 3 months after methotrexate to allow folate stores to replenish
Rh immunoglobulin
If your blood type is Rh-negative, you will receive a shot to protect future pregnancies
This is routinely given before discharge
Inform future obstetric care providers that you received this
References
Guidelines and key sources
Society and clinical guideline sources
ACOG Practice Bulletin on Ectopic Pregnancy
Recommendations on diagnosis, MTX dosing, and surgical criteria
ACEP Level A recommendation for MTX in stable unruptured ectopic
Society for Academic Emergency Medicine (SAEM) ectopic pregnancy position statement
POCUS role in ED evaluation ACEP Level B
Serial beta-hCG in pregnancy of unknown location ACEP Level B
Royal College of Obstetricians and Gynaecologists (RCOG) Green-top Guideline 21
Tubal ectopic pregnancy management standards
Laparoscopic salpingectomy as first-line surgical approach
Key evidence
ESEP trial (Randomized Trial of Salpingectomy vs Salpingostomy)
No significant difference in fertility outcomes at 36 months
Persistent trophoblast higher in salpingostomy arm
Serial beta-hCG and TVUS discriminatory zone evidence
Barnhart et al. studies defining rise thresholds 49-53% per 48 hours
TVUS sensitivity 99% specificity 84% when beta-hCG >1,500 IU/L
MTX single-dose efficacy data
Overall success 70-88% dependent on initial beta-hCG level
Success >90% when initial beta-hCG <1,000 mIU/mL
Coding standards
ICD-10 O00.10 tubal ectopic pregnancy without intrauterine pregnancy
ICD-10 O00.00 abdominal ectopic pregnancy without intrauterine pregnancy
ICD-10 O00.20 ovarian ectopic pregnancy without intrauterine pregnancy
SNOMED CT 79586000 tubal pregnancy
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.